Clinical trials: Stage II Colon Cancer
Colorectal Neoplasms, Metastases
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
This is a phase II, multicenter, open-label study of cetuximab in patients with epidermal growth factor receptor (EGFR) negative, metastatic colorectal carcinoma who have progressed after receiving at least one standard…
- Conditions
- Colorectal Neoplasms, Metastases, Neoplasm
- Trial name
- NCT00083720
- Testing
- cetuximab
- Where
- 27 sites in United States, Canada
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
This trial will evaluate the efficacy and safety of the capecitabine and oxaliplatine plus bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer.
- Trial name
- NCT01024504
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 6 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Colon Cancer, Colon Adenocarcinoma
Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery
Colon cancer is one of the most common cancers worldwide, and even after curative (radical) surgery, some patients develop recurrence or distant metastasis.
- Conditions
- Colon Cancer, Colon Adenocarcinoma, Colon Cancer Stage III, Colon Cancer Stage I
- Trial name
- STARS (NCT07167147)
- Where
- Taiwan
- Volunteers
- 7,259 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer
Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer
The purpose of this study is to determine confirmed objective response rate to combination therapy with cetuximab and FOLFOX4 or FOLFOX4 alone in patients with CRC and non-resectable hepatic metastases
- Trial name
- NCT00202787
- Testing
- FOLFOX-4+cetuximab, FOLFOX-4
- Where
- Spain
- Volunteers
- 136 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Cancer, Neoplasms
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Conditions
- Cancer, Neoplasms, Neoplasms, Breast, Tumor
- Trial name
- NCT06819215
- Testing
- VB15010
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Colorectal Cancer
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as S-1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00974389
- Testing
- bevacizumab, tegafur-gimeracil-oteracil potassium
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Osaka Medical College
Stage II Colon Cancer, Stage III Colon Cancer
Exercise and Colon Cancer
Despite the success of surgery and chemotherapy among people with colon cancer, 30-50% of patients develop recurrent disease. Physical activity has emerged as a potential lifestyle intervention to reduce cancer recurrence and…
- Trial name
- NCT02250053
- Testing
- Exercise
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Colorectal Cancer
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer
To estimate the progression free survival for subjects treated with panitumumab in combination with a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin (FOLFOX) as first-line chemotherapy regimen for…
- Trial name
- PULSE (NCT01288339)
- Testing
- Panitumumab + FOLFOX (DP), Panitumumab + FOLFOX (no-DP)
- Where
- 30 sites in Spain
- Volunteers
- 78 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581
This research trial studies tissue samples from patients with stage II colon cancer treated on Cancer and Leukemia Group B (CALGB)-9581 or CALGB-90903.
- Trial name
- NCT00897429
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2,059 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer (MSI-H)
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC): 1)…
- Trial name
- TORCH-OPTIMA (NCT07403877)
- Testing
- Nivolumab, Ipilimumab (1mg/kg), PULSAR
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
Colorectal Adenocarcinoma, Colon Cancer
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Data from a prior phase II study of single agent cabozantinib in metastatic, refractory colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal mouse models utilizing cabozantinib combined with…
- Conditions
- Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer
- Trial name
- NCT04963283
- Testing
- Cabozantinib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Colorado, Denver
Colorectal Cancer
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00055822
- Testing
- oblimersen sodium, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metastatic Colon Cancer
Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
The primary endpoint is to evaluate the Median disease progression free survival (mPFS).
- Trial name
- NCT02618356
- Testing
- Raltitrexed and S-1
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Colorectal Cancer
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077337
- Testing
- romidepsin
- Where
- 88 sites in United States
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer, Colorectal Adenocarcinoma
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
The goal of this clinical research study is to learn if adding brivanib to irinotecan can help control the disease in patients with colorectal cancer that has spread. The safety of this drug combination will also be studied.
- Trial name
- NCT01367275
- Testing
- Brivanib, Irinotecan
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and Avastin.
- Trial name
- NCT00717990
- Testing
- Capecitabine, Bevacizumab, Irinotecan
- Where
- Greece
- Volunteers
- 15 people
- Sponsor
- University Hospital of Crete
Colon Cancer, dMMR Colorectal Cancer
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.
- Trial name
- NAIO (NCT05239546)
- Testing
- Dostarlimab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Iowa
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients
1. Study Objectives 1) Primary Objective: Progression-free survival 2) Secondary Objectives: 1. overall survival 2. response rate 3. incidence, nature and severity of all adverse events 4. lipid lowering effect of simvastatin 5.
- Trial name
- NCT02026583
- Testing
- Simvastatin
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Samsung Medical Center
Colorectal Cancer
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
Colorectal cancer is an aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the feasibility, safety and efficacy of neoadjuvant oxaliplatin, irinotecan combined with…
- Trial name
- NCT02688023
- Testing
- oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese Academy of Medical Sciences